Pathogenic role of TGF-ß in the progression of podocyte diseases

Histology and Histopathology

Volumn 26, Issue 1, 2011, Pages 107-116

  Lee, Hyun Soon ^a  

^a Seoul National University   (South Korea)

Author keywords

Angiotensin II; Biomechanical strain; Glomerular basement membrane thickening; Mesangial matrix expansion; Oxidative stress; Podocyte apoptosis

Indexed keywords

ANGIOTENSIN II; CONNECTIVE TISSUE GROWTH FACTOR; CTGF PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL; BIOLOGICAL MODEL; BIOMECHANICS; DENYS DRASH SYNDROME; DIABETIC NEPHROPATHY; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; KIDNEY DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; PARACRINE SIGNALING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PODOCYTE; RENOVASCULAR HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; BIOMECHANICS; CONNECTIVE TISSUE GROWTH FACTOR; DENYS-DRASH SYNDROME; DIABETIC NEPHROPATHIES; GLOMERULAR BASEMENT MEMBRANE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; HYPERTENSION, RENAL; KIDNEY DISEASES; MODELS, BIOLOGICAL; PARACRINE COMMUNICATION; PODOCYTES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78651259529     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Abbate M., Zoja C., Morigi M., Rottoli D., Angioletti S., Tomasoni S., Zanchi C., Longaretti L., Donadelli R. and Remuzzi G. (2002). Transforming growth factor-ß1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am. J. Pathol. 161, 2179-2193.
2. Abrahamson D., Prettyman A., Robert B. and St John P. L. (2003). Laminin-1 reexpression in Alport mouse glomerular basement membranes. Kidney Int. 63, 826-834.
3. Abrahamson D. R., Hudson B. G., Stroganova L., Borza D.-B. and St. John P. L. (2009). Cellular origins of type IV collagen networks in developing glomeruli. J. Am. Soc. Nephrol. 20, 1471-1479.
4. Baba M., Wada J., Eguchi J., Hashimoto I., Okada T., Yasuhara A., Shikata K., Kanwar Y. S. and Makino H. (2005). Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycledependent mechanisms. J. Am. Soc. Nephrol. 16, 3222-3234.
5. Bailey E., Bottomley M. J., Westwell S., Pringle J. H., Furness P. N., Feehally J., Brenchley P. E. C. and Harper S. J. (1999). Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by nonisotopic in situ hybridization. J. Clin. Pathol. 52, 735-738.
6. Benigni A., Zoja C., Corna D., Zatelli C., Conti S., Campana M., Gagliardini E., Rottoli D., Zanchi C., Abbate M., Ledbetter S. and Remuzzi G. (2003). Add-on anti-TGF-ß antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 14, 1816-1824.
7. Benter I. F., Yousif M. H., Dhaunsi G. S., Kaur J., Chappell M. C. and Diz D. I. (2008). Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am. J. Nephrol. 28, 25-33.
8. Chai Q., Krag S., Miner J. H., Nyengaard J. R., Chai S. and Wogensen L. (2003). TGF-ß1 induces aberrant laminin chain and collagen type IV isotype expression in the glomerular basement membrane. Nephron Exp. Nephrol. 94, e123-e136.
9. Chen C. A., Hwang J. C., Guh J. Y., Chang J. M., Lai Y. H. and Chen H. C. (2006). Reduced podocyte expression of α3ß1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats. J. Lab. Clin. Med. 147, 74-82.
10. Chen H. C., Chen C. A., Guh J. Y., Chang J. M., Shin S. J. and Lai Y. H. (2000). Altering expression of α3ß1 integrin on podocytes of human and rats with diabetes. Life Sci. 67, 2345-2353.
11. Chen S., Iglesias-de la Cruz M. C., Jim B., Hong S. W., Isono M. and Ziyadeh F. N. (2003). Reversibility of established diabetic glomerulopathy by anti-TGF-ß antibodies in db/db mice. Biochem. Biophys. Res. Commun. 300, 16-22.
12. Chen S., Kasama Y., Lee J. S., Jim B., Marin M. and Ziyadeh F. N. (2004). Podocyte-derived vascular endothelial growth factor mediates the stimulation of α3 (IV) collagen production by transforming growth factor-ß1 in mouse podocytes. Diabetes 53, 2939-2949.
13. Chen S., Lee J. S., Iglesias-de la Cruz M. C., Wang A., Izquierdo-Lahuerta A., Gandhi N. K., Danesh F. R., Wolf G. and Ziyadeh F. N. (2005). Angiotensin II stimulates α3 (IV) collagen production in mouse podocytes via TGF-ß and VEGF signaling: implications for diabetic glomerulopathy. Nephrol. Dial. Transplant. 20, 1320-1328.
14. Cosgrove D., Rodgers K., Meehan D., Miller C., Bovard K., Gilroy A., Gardner H., Kotelianski V., Gotwals P., Amatucci A. and Kalluri R. (2000). Integrin α1ß1 and transforming growth factor-ß1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am. J. Pathol. 157, 1649-1659.
15. Couser W. G. and Nangaku M. (2006). Cellular and molecular biology of membranous nephropathy. J. Nephrol. 19, 699-705.
16. Cruzado J. M., Lloberas N., Torras J., Riera M., Fillat C., Herrero-Fresneda I., Aran J. M., Alperovich G., Vidal A. and Grinyo J. M. (2004). Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes 53, 1119-1127.
17. Cui T.-G., Foster R. R., Saleem M., Mathieson P. W., Gillatt D. A., Bates D. O. and Harper S. J. (2004). Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. Am. J. Physiol. Renal Physiol. 286, F767-773.
18. Dai C. and Liu Y. (2004). Hepatocyte growth factor antagonizes the profibrotic action of TGF-ß in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J. Am. Soc. Nephrol. 15, 1402-1412.
19. Dessapt C., Baradez M. O., Hayward A., Dei Cas A., Thomas S. M., Viverti G. and Gnudi L. (2009). Mechanical forces and TGFß1 reduce podocyte adhesion through α3ß1 integrin downregulation. Nephrol. Dial. Transplant. 24, 2645-2655.
20. Drummond K. and Mauer M. (2002). The early natural history of nephropathy in type 1 diabetes. II. Early renal structural changes in type 1 diabetes. Diabetes 51, 1580-1587.
21. Durvasula R. V., Pettermann A. T., Hiromura K., Blonski M., Pippin J., Mundel P., Pichler R., Griffin S., Couser W. G. and Shankland S. J. (2004). Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 65, 30-39.
22. Fischer E., Mougenot B., Callard P., Ronco P. and Rossert J. (2000). Abnormal expression of glomerular basement membrane laminins in membranous glomerulonephritis. Nephrol. Dial. Transplant. 15, 1956-1964.
23. Flyvbjerg A., Dagnaes-Hansen F., De Vriese A. S., Schrijvers B. F., Tilton R. G. and Rasch R. (2002). Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51, 3090-3094.
24. Fukasawa H., Yamamoto T., Togawa A., Ohashi N., Fujigaki Y., Oda T., Uchida C., Kitagawa K., Hattori T., Suzuki S., Kitagawa M. and Hishida A. (2006). Ubiquitin-dependent degradation of SnoN and Ski is increased in renal fibrosis induced by obstructive injury. Kidney Int. 69, 1733-1740.
25. Gregory M. C., Terreros D. A., Barker D. F., Fain P. N., Denison J. C. and Atkin C. L. (1996). Alport syndrome-clinical phenotypes, incidence, and pathology. Contrib. Nephrol. 117, 1-28.
26. Gross O. and Kashtan C. E. (2009). Treatment of Alport syndrome: beyond animal models. Kidney Int. 76, 599-603.
27. Gross O., Beirowski B., Koepke M.-L., Kuck J., Reiner M., Addicks K., Smyth N., Schulze-Lohoff E. and Weber M. (2003). Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 63, 438-446.
28. Gross O., Schulze-Lohoff E., Koepke M.-L., Beirowski B., Addicks K., Bloch W., Smyth N. and Weber M. (2004). Antifibrotic, nephroprotective potential of ACE-inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol. Dial. Transplant. 19, 1716-1723.
29. Han D. C., Hoffman B. B., Hong S. W., Guo J. and Ziyadeh F. N. (2000). Therapy with antisense TGF-ß1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am. J. Physiol. Renal Physiol. 278, F628-F634.
30. Hirschberg R. (2005). Wound healing in the kidney: complex interactions in renal interstitial fibrogenesis. J. Am. Soc. Nephrol. 16, 9-11.
31. Honkanen E., von Willebrand E., Koskinen P., Teppo A.-M., Törnroth T., Ruutu M. and Grönhagen-Riska C. (2003). Decreased expression of vascular endothelial growth factor in idiopathic membranous glomerulonephritis: relationships to clinical course. Am. J. Kidney Dis. 42, 1139-1148.
32. Hou C. C., Wang W., Huang X. R., Fu P., Chen T. H., Sheikh-Hamad D. and Lan H. Y. (2005). Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-ß signaling and fibrosis in rat remnant kidney. Am. J. Pathol. 166, 761-771.
33. Iglesias-de la Cruz M. C., Ziyadeh F. N., Isono M., Kouahou M., Han D. C., Kalluri R., Mundel P. and Chen S. (2002). Effects of high glucose and TGF-ß1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int. 62, 901-913.
34. Ito Y., Aten J., Bende R. J., Oemar B. S., Rabelink T. J., Weening J. J. and Goldschmeding R. (1998). Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 53, 853-861.
35. Ito Y., Goldschmeding R., Bende R. J., Claessen N., Chand M. A., Kleij L., Rabelink T. J., Weening J. J. and Aten J. (2001). Kinectics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J. Am. Soc. Nephrol. 12, 472-484.
36. Jin D. K., Kang S. I., Kim S. L., Bang E. H., Hwang H. Z., Tadokoro K., Yamada M. and Kohsaka T. (1999). Transcriptional regulation of PDGF-A and TGF-ß by +KTS WT1 deletion mutants and a mutant mimicking Denys-Drash syndrome. Renal Fail. 21, 685-694.
37. Kagami S., Border W. A., Ruoslahti E. and Noble N. A. (1993). Coordinated expression of ß1 integrins and TGF-ß-induced matrix proteins in glomerulonephritis. Lab. Invest. 69, 68-76.
38. Kalluri R., Shield III C. F., Todd P., Hudson B. G. and Nielson E. G. (1997). Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membrane to endoproteolysis. J. Clin. Invest. 99, 2470-2478.
39. Kashtan C., Kim Y., Lees G. E., Thorner P. S., Virtanen I. and Miner J. H. (2001). Abnormal glomerular basement membrane laminins in murine, canine and human Alport syndrome: aberrant laminin α2 deposition is species independent. J. Am. Soc. Nephrol. 12, 252-260.
40. Katavetin P. and Katavetin P. (2008). VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 359, 205-206.
41. Kim B. K., Hong H. K., Kim J. H. and Lee H. S. (2002). Differential expression of nephrin in acquired human proteinuric diseases. Am. J. Kidney Dis. 40, 964-973.
42. Kim H. W., Kim B. C., Song C. Y., Kim J. H., Hong H. K. and Lee H. S. (2004). Heterozygous mice for TGF-ßIIR gene are resistant to the progression of streptozotocin-induced diabetic nephropathy. Kidney Int. 66, 1859-1865.
43. Kim J. H., Kim B. K., Moon K. C., Hong H. K. and Lee H. S. (2003). Activation of the TGF-ß/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int. 64, 1715-1721.
44. Kim K. H., Kim Y., Gubler M. C., Steffes M. W., Lane P. H., Kashtan C. E., Crosson J. T. and Mauer S. M. (1995). Structural-functional relationships in Alport syndrome. J. Am. Soc. Nephrol. 5, 1659-1668.
45. Kim T. S., Kim J. Y., Hong H. K. and Lee H. S. (1999). mRNA expression of glomerular basement membrane proteins and TGF-ß1 in human membranous nephropathy. J. Pathol. 189, 425-430.
46. Krag S., Nyengaard J. R. and Wogensen L. (2007). Combined effects of moderately elevated blood glucose and locally produced TGF-ß1 on glomerular morphololgy and renal collagen production. Nephrol. Dial. Transplant. 22, 2485-2496.
47. Kreidberg J. A. and Symons J. M. (2000). Integrins in kidney development, function and disease. Am. J. Physiol. Renal Physiol. 279, F233-F242.
48. Kriz W. and LeHir M. (2005). Pathways to nephron loss starting from glomerular diseases-Insights from animal models. Kidney Int. 67, 404-419.
49. Kriz W., Gretz N. and Lemley K. V. (1998). Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int. 54, 687-697.
50. Lee H. S. and Koh H. I. (1993). Nature of progressive glomerulosclerosis in human membranous nephropathy. Clin. Nephrol. 39, 7-16.
51. Lee H. S. and Lim S. D. (1995). The significance of glomerular hypertrophy in focal segmental glomerulosclerosis. Clin. Nephrol. 44, 349-355.
52. Lee H. S. and Song C. Y. (2009). Differential role of mesangial cells and podocytes in TGF-ß-induced mesangial matrix synthesis in chronic glomerular disease. Histol. Histopathol. 24, 901-908.
53. Lee H. S. and Song C. Y. (2010). Effects of TGF-ß on podocyte growth and disease progression in proliferative podocytopathies. Kidney Blood Press. Res. 33, 24-29.
54. Lee L. K., Pollock A. S. and Lovett D. H. (1993). Asymmetric origins of the mature glomerular basement membrane. J. Cell Physiol. 157, 169-177.
55. Li Y., Kang Y. S., Dai C., Kiss L. P., Wen X. and Liu Y. (2008). Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am. J. Pathol. 172, 299-308.
56. Liu S., Liang Y., Huang H., Wang L., Li Y., Li J., Li X. and Wang H. (2005). ERK-dependent signaling pathway and transcriptional factor Ets-1 regulate matrix metalloproteinase-9 production in transforming growth factor-ß1 stimulated glomerular podocytes. Cell Physiol. Biochem. 16, 207-216.
57. Liu Y. (2004). Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am. J. Physiol. Renal Physiol. 287, F7-F16.
58. Liu Y. (2010). New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol. 21, 212-222.
59. Matsusaka T., Xin J., Niwa S., Kobayashi K., Akatsuka A., Hashizume H., Wang Q-c., Pastan I., Fogo A. B. and Ichikawa I. (2005). Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J. Am. Soc. Nephrol. 16, 1013-1023.
60. Mazzucco G., de Marchi M. and Monga G. (2002). Renal biopsy interpretation in Alport syndrome. Sem. Diag. Pathol. 19, 133-145.
61. McMillan J. I., Riordan J. W., Couser W. G., Pollock A. S. and Lovett D. H. (1996). Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J. Clin. Invest. 97, 1094-1101.
62. Meehan D. T., Delimont D., Cheung L., Zallocchi M., Sansom S. C., Holzclaw J. D., Rao V. and Cosgrove D. (2009). Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease. Kidney Int. 76, 968-976.
63. Miner J. H. (1999). Renal basement membrane components. Kidney Int. 56, 2016-2024.
64. Miner J. H. (2005). Building the glomerulus: a matricentric view. J. Am. Soc. Nephrol. 16, 857-861.
65. Mundel P. and Shankland S. J. (2002). Podocyte biology and response to injury. J. Am. Soc. Nephrol. 13, 3005-3015.
66. Okada T., Wada J., Hida K., Eguchi J., Hashimoto I., Baba M., Yasuhara A., Shikata K. and Makino H. (2006). Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 55, 1666-1677.
67. Patek C. E., Fleming S., Miles C. G., Bellamy C. O., Ladomery M., Spraggon L., Mullins J., Hastie N. D. and Hooper M. L. (2003). Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis. Hum. Mol. Genet. 12, 2379-2394.
68. Petersen M., Thorikay M., Deckers M., van Dinther M., Grygielko E. T., Gellibert F., de Gouville A. C., Huet S., ten Dijke P. and Laping N. J. (2008). Oral administration of GW788388, an inhibitor of TGF-ß type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 73:705-715.
69. Remuzzi A., Monaci N., Bonassi M. E., Corna D., Zoja C., Mohammed E. I. and Remuzzi G. (1999). Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive heymann nephritis. Lab. Invest. 79, 1501-1510.
70. Russo L. M., del Re E., Brown D. and Lin H. Y. (2007). Evidence for a role of transforming growth factor (TGF)-ß1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-ß type II receptor. Diabetes 56, 380-388.
71. Sayers R., Kalluri R., Rodgers K. D., Shield III C. F., Meehan D. T. and Cosgrove D. (1999). Role for transforming growth factor-ß1 in Alport renal disease progression. Kidney Int. 56, 1662-1673.
72. Schiffer M., Bitzer M., Roberts I. S. D., Kopp J. B., ten Dijke P., Mundel P. and Böttinger E. P. (2001). Apoptosis in podocytes induced by TGF-ß and Smad7. J. Clin. Invest. 108, 807-816.
73. Schiffer M., Mundel P., Shaw A. S. and Böttinger E. P. (2004). A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-ß-induced apoptosis. J. Biol. Chem. 279, 37004-37012
74. Shankland S. J., Pippin J., Pichler R. H., Gordon K. L., Friedman S., Gold L. I., Johnson R. J. and Couser W. G. (1996). Differential expression of transforming growth factor-ß isoforms and receptors in experimental membranous nephropathy. Kidney Int. 50, 116-124.
75. Shibata S., Nagase M., Yoshida S., Kawachi H. and Fujita T. (2007). Podocyte as the target for aldosteone. Roles of oxidative stress and Sgk1. Hypertension 49, 355-364.
76. Shulman K., Rosen S., Tognazzi K., Manseau E. J. and Brown L. F. (1996). Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J. Am. Soc. Nephrol. 7, 661-666.
77. Siviridis E., Giatromanolaki A., Touloupidis S., Pasadakis P. and Vargemezis V. (2003). Platelet endothelial cell adhesion molecule-1 and angiogenic factor expression in idiopathic membranous nephropathy. Am. J. Kidney Dis. 41, 360-365.
78. Strehlau J., Schachter A. D., Pavlakis M., Singh A., Tejani A. and Strom T. B. (2002). Activated intrarenal transcription of CTL-effectors and TGF-ß1 in children with focal segmental glomerulosclerosis. Kidney Int. 61, 90-95.
79. Sung S. H., Ziyadeh F. N., Wang A., Pyagay P. E., Kanwar Y. S. and Chen S. (2006). Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol. 17, 3093-3104.
80. Suzuki D., Toyoda M., Umezono T., Uehara G., Zhang S.-Y., Sakai T., Nishina M., Suga T., Endoh M., Yagame M. and Sakai H. (2003). Glomerular expression of connective tissue growth factor mRNA in various renal diseases. Nephrology 8, 92-97.
81. Tojo A., Asaba K. and Onozato M. L. (2007). Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin. Ther. Targets 11, 1011-1018.
82. Vieitez P., Gomez O., Uceda E. R., Vera M. E. and Molina-Holgado E. (2008). Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. J. Renin Angiotensin Aldosterone Syst. 9, 96-102.
83. Wahab N. A., Schaefer L., Weston B. S., Yiannikouris O., Wright A., Babelova A., Schaefer R. and Mason R. M. (2005). Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 48, 2650-2660.
84. Wang A., Ziyadeh F. N., Lee E. Y., Pyagay P. E., Sung S. H., Sheardown S. A., Laping N. J. and Chen S. (2007). Interference with TGF-ß signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am. J. Physiol. Renal Physiol. 293, F1657-F1665.
85. Wang S. and Hirschberg R. (2004). Bone morphogenetic protein-7 signals opposing transforming growth factor ß in mesangial cells. J. Biol. Chem. 279, 23200-23206.
86. Wang S., de Caestecker M., Kopp J., Mitu G., LaPage J. and Hirschberg R. (2006). Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J. Am. Soc. Nephrol. 17, 2504-2512.
87. Wendt T. M., Tanji N., Guo J., Kislinger T. R., Qu W., Lu Y., Bucciarelli L. G., Rong L. L., Moser B., Markowitz G. S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P. P., Stern D. M., D'Agati V. D. and Schmidt A. M. (2003). RAGE drives the develolpment of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123-1137.
88. Whaley-Connell A., Habibi J., Nistala R., Cooper S. A., Karuparthi P. R., Hayden M. R., Rehmer N., DeMarco V. G., Andresen B. T., Wei Y., Ferrario C. and Sowers J. R. (2008). Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 51, 474-480.
89. Wogensen L., Nielsen C. B., Hjorth P., Rasmussen L. M., Nielsen A. H., Gross K., Sarvetnick N. and Ledet T. (1999). Under control of the Ren-1c promoter, locally produced transforming growth factor-ß1 induces accumulation of glomerular extracellular matrix in transgenic mice. Diabetes 48, 182-192.
90. Wolf G., Chen S. and Ziyadeh F. N. (2005). From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54, 1626-1634.
91. Yang A. H., Chen J. Y. and Chen B. F. (2004). The dysregulated glomerular cell growth in Denys-Drash syndrome. Virchows Arch. 445, 305-314.
92. Yang J., Zhang X., Li Y. and Liu Y. (2003). Downregulation of Smad transcriptional corepressors SnoN and Ski in the fibrotic kidney: an amplification mechanism for TGF-ß1 signaling. J. Am. Soc. Nephrol. 14, 3167-3177.
93. Yaswen L., Kulkarni A. B., Fredrickson T., Mittleman B., Schiffman R., Payne S., Longenecker G., Mozes E. and Karlsson S. (1996). Autoimmune manifestations in the transforming growth factor-ß1 knockout mouse. Blood 87, 1439-1445.
94. Yokoi H., Mukoyama M., Mori K., Kasahara M., Suganami T., Sawai K., Yoshioka T., Saito Y., Ogawa Y., Kuwabara T., Sugawara A. and Nakao K. (2008). Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int. 73, 446-455.
95. Zeisberg M. (2006). Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol. Dial. Transplant. 21, 568-573.
96. Zeisberg M., Bottiglio C., Kumar N., Maeshima Y., Strutz F., Muller G. A. and Kalluri R. (2003). Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Phsiol. Renal Physiol. 285, F1060-F1067.
97. Zeisberg M., Khurana M., Rao V. H., Cosgrove D., Rougier J. P., Werner M. C., Shield III C. F., Werb Z. and Kalluri R. (2006). Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med. 3, e100.
98. Zhang Y. and Lee H. S. (1997). Quantitative changes in the glomerular basement membrane components in human membranous nephropathy. J. Pathol. 183, 8-15.
99. Ziyadeh F. N. and Wolf G. (2008). Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr. Diabetes Rev. 4, 39-45.
100. Ziyadeh F. N., Hoffman B. B., Han D. C., Iglesias-de la Cruz M. C., Hong S. W., Isono M., Chen S., McGowan T. A. and Sharma K. (2000). Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-ß antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97, 8015-8020.